sales@angenesci.com
Login | Register
logo
Structures Search
Home Halogens N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)Methyl)piperazine-1-carboxaMide

N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)Methyl)piperazine-1-carboxaMide

CAS No.:
1346528-50-4
Catalog Number:
AG009CKZ
Molecular Formula:
C18H17ClF2N4O3
Molecular Weight:
410.8024
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$105
- +
5mg
≥98%
1 week
United States
$251
- +
10mg
≥98%
1 week
United States
$348
- +
25mg
≥98%
1 week
United States
$604
- +
100mg
99%
1 week
United States
$1707
- +
Product Description
Catalog Number:
AG009CKZ
Chemical Name:
N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)Methyl)piperazine-1-carboxaMide
CAS Number:
1346528-50-4
Molecular Formula:
C18H17ClF2N4O3
Molecular Weight:
410.8024
MDL Number:
MFCD29047142
IUPAC Name:
N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
InChI:
InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
InChI Key:
YWGYNGCRVZLMCS-UHFFFAOYSA-N
SMILES:
O=C(N1CCN(CC1)Cc1ccc2c(c1)OC(O2)(F)F)Nc1cnccc1Cl
UNII:
AH2E5UQ11Y
Properties
Complexity:
565  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
410.096g/mol
Formal Charge:
0
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
410.806g/mol
Monoisotopic Mass:
410.096g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
66.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.6  
Literature
Title Journal
Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS medicinal chemistry letters 20151210
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20140214
Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. The Proceedings of the Nutrition Society 20140201
Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. International review of psychiatry (Abingdon, England) 20090401
Properties